Nkarta's CAR NK Cell Therapy Shows Early Positive Results in Autoimmune Diseases

Nkarta announced initial positive clinical data from its Ntrust trial for NKX019, an allogeneic CAR NK cell therapy, in autoimmune diseases. Presented at ACR Convergence 2026, the data indicated good tolerability and early efficacy, with 83% of myositis and 86% of systemic sclerosis patients showing moderate or major responses at the 4 billion-cell dose. This represents a promising development for these conditions.